The effect of combretastatin A4 disodium phosphate and 5,6-dimethylxanthenone-4-acetic acid on water diffusion and blood perfusion in tumours

References

• Kerbel RS. Tumor angiogenesis: Past, present and the near future. Carcinogenesis 2000; 21: 505–15
   PubMed Web of Science ®Google Scholar
• Vaupel P, Kallinowski F, Okunieff P. Blood flow, oxygen and nutrient supply, and metabolic microenvironment of human tumors: A review. Cancer Res 1989; 49: 6449–65
   PubMed Web of Science ®Google Scholar
• Siemann DW, Warrington KH, Horsman MR. Targeting tumor blood vessels: An adjuvant strategy for radiation therapy. Radiother Oncol 2000; 57: 5–12
   PubMed Web of Science ®Google Scholar
• Murata R, Overgaard J, Horsman MR. Combretastatin A-4 disodium phosphate: A vascular targeting agent that improves that improves the anti-tumor effects of hyperthermia, radiation, and mild thermoradiotherapy. Int J Radiat Oncol Biol Phys 2001; 51: 1018–24
   PubMed Web of Science ®Google Scholar
• Pettit GR, Singh SB, Hamel E, Lin CM, Alberts DS, Garcia-Kendall D. Isolation and structure of the strong cell growth and tubulin inhibitor combretastatin A-4. Experientia 1989; 45: 209–11
   PubMedGoogle Scholar
• Woods JA, Hadfield JA, Pettit GR, Fox BW, McGown AT. The interaction with tubulin of a series of stilbenes based on combretastatin A-4. Br J Cancer 1995; 71: 705–11
   PubMed Web of Science ®Google Scholar
• Dark GG, Hill SA, Prise VE, Tozer GM, Pettit GR, Chaplin DJ. Combretastatin A-4, an agent that displays potent and selective toxicity toward tumor vasculature. Cancer Res 1997; 57: 1829–34
   PubMed Web of Science ®Google Scholar
• Galbraith SM, Maxwell RJ, Lodge MA, Tozer GM, Wilson J, Taylor NJ, et al. Combretastatin A4 phosphate has tumor antivascular activity in rat and man as demonstrated by dynamic magnetic resonance imaging. J Clin Oncol 2003; 21: 2831–42
   PubMed Web of Science ®Google Scholar
• Zwi LJ, Baguley BC, Gavin JB, Wilson WR. The morphological effects of the anti-tumor agents flavone acetic acid and 5,6-dimethyl xanthenone acetic acid on the colon 38 mouse tumor. Pathology 1994; 26: 161–9
   PubMed Web of Science ®Google Scholar
• Ching LM, Goldsmith D, Joseph WR, Korner H, Sedgwick JD, Baguley BC. Induction of intratumoral tumor necrosis factor (TNF) synthesis and hemorrhagic necrosis by 5,6-dimethylxanthenone-4-acetic acid (DMXAA) in TNF knockout mice. Cancer Res 1999; 59: 3304–7
   PubMed Web of Science ®Google Scholar
• Beauregard DA, Pedley RB, Hill SA, Brindle KM. Differential sensitivity of two adenocarcinoma xenografts to the anti-vascular drugs combretastatin A4 phosphate and 5,6-dimethylxanthenone-4-acetic acid, assessed using MRI and MRS. NMR Biomed 2002; 15: 99–105
   PubMed Web of Science ®Google Scholar
• Murata R, Overgaard J, Horsman MR. Comparative effects of combretastatin A-4 disodium phosphate and 5,6-dimethylxanthenone-4-acetic acid on blood perfusion in a murine tumour and normal tissues. Int J Radiat Biol 2001; 77: 195–204
   PubMed Web of Science ®Google Scholar
• Chen G, Jespersen SN, Pedersen M, Pang Q, Horsman MR, Stodkilde-Jorgensen H. Intravenous administration of Gd-DTPA prior to DWI does not affect the apparent diffusion constant. Magn Reson Imaging 2005; 23: 685–9
   PubMedGoogle Scholar
• Zhao D, Jiang L, Hahn EW, Mason RP. Tumor physiologic response to combretastatin A4 phosphate assessed by MRI. Int J Radiat Oncol Biol Phys 2005; 62: 872–80
   PubMed Web of Science ®Google Scholar
• Chen G, Jespersen S, Pedersen M, Pang Q, Horsman MR, Stodkilde-Jorgensen H. Evaluation of anti-vascular therapy with texture analysis. Anticancer Res 2005; 25: 3399–405
   PubMedGoogle Scholar
• Gass A, Niendorf T, Hirsch JG. Acute and chronic changes of the apparent diffusion coefficient in neurological disorders--biophysical mechanisms and possible underlying histopathology. J Neurol Sci 2001; 186(Suppl 1)S15–S23
   PubMedGoogle Scholar
• Le BD. Molecular diffusion, tissue microdynamics and microstructure. NMR Biomed 1995; 8: 375–86
   PubMedGoogle Scholar
• Zhao M, Pipe JG, Bonnett J, Evelhoch JL. Early detection of treatment response by diffusion-weighted 1H-NMR spectroscopy in a murine tumour in vivo. Br J Cancer 1996; 73: 61–4
   PubMedGoogle Scholar
• Chenevert TL, Mckeever PE, Ross BD. Monitoring early response of experimental brain tumors to therapy using diffusion magnetic resonance imaging. Clin Cancer Res 1997; 3: 1457–66
   PubMed Web of Science ®Google Scholar
• Poptani H, Puumalainen AM, Grohn OH, Loimas S, Kainulainen R, Yla-Herttuala S, et al. Monitoring thymidine kinase and ganciclovir-induced changes in rat malignant glioma in vivo by nuclear magnetic resonance imaging. Cancer Gene Ther 1998; 5: 101–9
   PubMedGoogle Scholar
• Lyng H, Haraldseth O, Rofstad EK. Measurement of cell density and necrotic fraction in human melanoma xenografts by diffusion weighted magnetic resonance imaging. Magn Reson Med 2000; 43: 828–36
   PubMed Web of Science ®Google Scholar
• Lang P, Wendland MF, Saeed M, Gindele A, Rosenau W, Mathur A, et al. Osteogenic sarcoma: Noninvasive in vivo assessment of tumor necrosis with diffusion-weighted MR imaging. Radiology 1998; 206: 227–35
   PubMedGoogle Scholar
• Vossen JA, Buijs M, Kamel IR. Assessment of tumor response on MR imaging after locoregional therapy. Tech Vasc Interv Radiol 2006; 9: 125–32
   PubMedGoogle Scholar
• Buijs M, Kamel IR, Vossen JA, Georgiades CS, Hong K, Geschwind JF. Assessment of metastatic breast cancer response to chemoembolization with contrast agent enhanced and diffusion-weighted MR imaging. J Vasc Interv Radiol 2007; 18: 957–63
   PubMed Web of Science ®Google Scholar
• Tozer GM, Kanthou C, Baguley BC. Disrupting tumour blood vessels. Nat Rev Cancer 2005; 5: 423–35
   PubMed Web of Science ®Google Scholar
• Galbraith SM, Rustin GJ, Lodge MA, Taylor NJ, Stirling JJ, Jameson M, et al. Effects of 5,6-dimethylxanthenone-4-acetic acid on human tumor microcirculation assessed by dynamic contrast-enhanced magnetic resonance imaging. J Clin Oncol 2002; 20: 3826–40
   PubMed Web of Science ®Google Scholar
• Jameson MB, Baguley BC, Kestell P, Zhao L, Paxton JW, Thompson PI, Waller S Pharmacokinetics of 5,6-dimethylxanthenone-4-acetic acid (AS1404), a novel vascular disrupting agent, in phase I clinical trial. Cancer Chemother Pharmacol 2007;59:681–687.
   PubMed Web of Science ®Google Scholar
• Rustin GJ, Bradley C, Galbraith S, Stratford M, Loadman P, Waller S, et al. 5,6-dimethylxanthenone-4-acetic acid (DMXAA), a novel antivascular agent: Phase I clinical and pharmacokinetic study. Br J Cancer 2003; 88: 1160–7
   PubMed Web of Science ®Google Scholar
• Zhou S, Kestell P, Baguley BC, Paxton JW. 5,6-dimethylxanthenone-4-acetic acid (DMXAA): A new biological response modifier for cancer therapy. Invest New Drugs 2002; 20: 281–95
   PubMed Web of Science ®Google Scholar